Harmonic Pharma is committed to delivering innovative cancer therapies with the aim of making a meaningful impact on patient life.

We are currently focusing our pipeline on Non Small Cell Lung Cancer (NSCLC) and Uveal Melanoma (UM).

Harmonic Pharma’s pipeline comprises a selection of drugs with a known safety profile that can be evaluated rapidly in phase II, once efficacy in the novel selected indication is demonstrated.


NSCLC indication : Harmonic’s drug candidate HPH112 shows an original mechanism of action (MoA) for lung cancer. HPH112 has shown significant tumor growth inhibition in different Patient Derived Xenografts (PDXs) that reflect clinical conditions of the selected indication [Institut Curie proprietary tumor collection].  Efficacy assessment has been performed in monotherapy and in combination with standard of care. Safety profile of HPH112 has previously been thoroughly investigated in man and confirmed for the newly identified use in oncology. HPH112 is ready for Proof of Concept (PoC) in man. A multicentric clinical trial has been designed.

UM indication : Harmonic’s drug candidate HPH196 and HPH211 have shown significant tumor growth inhibition in different PDXs that reflect clinical conditions of UM for which Institut Curie is the reference center in France. These first results make HPH196 and HPH211 good candidates for further evaluation.

Licensing opportunities : Our business model is based on licensing and agreements for the development of drug candidates. If you are interested in licensing or development opportunities please contact us.